SPRO - Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference | Benzinga
CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at Cantor Fitzgerald's Global Healthcare 2023 Investor Conference, which will be held on September 26-28, 2023, at the Intercontinental Barclay Hotel in New York, NY. Details are as follows:
Cantor Global Healthcare 2023
Fireside Chat: Tuesday, September 26, 2023, from 4:20 PM-4:50 PM ET
Webcast Link: https://wsw.com/webcast/cantor19/spro/2127972
The webcast may also be accessed through Spero Therapeutics' website (www.sperotherapeutics.com) on the "Events and Presentations" page under the "Connect" tab. Replays will be available on the website following the conclusion of each event.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.
- Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.
- Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by ...